MCID: ABD014
MIFTS: 52

Abdominal Obesity-Metabolic Syndrome 1 malady

Categories: Genetic diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Abdominal Obesity-Metabolic Syndrome 1

Aliases & Descriptions for Abdominal Obesity-Metabolic Syndrome 1:

Name: Abdominal Obesity-Metabolic Syndrome 1 54 12
Metabolic Syndrome X 12 29 52 42 14 69
Abdominal Obesity Metabolic Syndrome 69
Dysmetabolic Syndrome X 12
Metabolic Diseases 69
Metabolic Disorder 14

Classifications:



External Ids:

OMIM 54 605552
Disease Ontology 12 DOID:14221
ICD9CM 35 277.7
MeSH 42 D024821
NCIt 47 C84442
SNOMED-CT 64 190394009 237602007
UMLS 69 C0524620

Summaries for Abdominal Obesity-Metabolic Syndrome 1

OMIM : 54 A clustering of abdominal obesity, high triglycerides, low levels of high density lipoprotein cholesterol (HDLC), high... (605552) more...

MalaCards based summary : Abdominal Obesity-Metabolic Syndrome 1, also known as metabolic syndrome x, is related to pyrimidine metabolic disorder and carbohydrate metabolic disorder, and has symptoms including emaciation, angina pectoris and chest pain. An important gene associated with Abdominal Obesity-Metabolic Syndrome 1 is MTTP (Microsomal Triglyceride Transfer Protein), and among its related pathways/superpathways are Metabolism and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Ezetimibe and Simvastatin have been mentioned in the context of this disorder. Related phenotypes are homeostasis/metabolism and growth/size/body region

Related Diseases for Abdominal Obesity-Metabolic Syndrome 1

Diseases in the Abdominal Obesity-Metabolic Syndrome family:

Abdominal Obesity-Metabolic Syndrome 1 Abdominal Obesity-Metabolic Syndrome 3

Diseases related to Abdominal Obesity-Metabolic Syndrome 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 275)
id Related Disease Score Top Affiliating Genes
1 pyrimidine metabolic disorder 32.9 ADIPOQ APOB INS LPL SERPINE1
2 carbohydrate metabolic disorder 12.3
3 lipid metabolism disorder 12.3
4 amino acid metabolic disorder 12.2
5 purine-pyrimidine metabolic disorder 12.1
6 bilirubin metabolic disorder 12.1
7 metal metabolism disorder 12.0
8 inherited metabolic disorder 12.0
9 gamma-amino butyric acid metabolism disorder 12.0
10 vitamin metabolic disorder 12.0
11 steroid inherited metabolic disorder 12.0
12 inborn amino acid metabolism disorder 11.7
13 urea cycle disorder 11.5
14 organic acidemia 11.3
15 iron metabolism disease 11.3
16 lysosomal storage disease 11.2
17 porphyria 11.2
18 phenylketonuria 11.1
19 galactosemia 11.1
20 trimethylaminuria 11.1
21 alkaptonuria 11.1
22 mineral metabolism disease 11.0
23 zinc, elevated plasma 11.0
24 phosphorus metabolism disease 11.0
25 hemochromatosis 11.0
26 fumarase deficiency 11.0
27 lysinuric protein intolerance 11.0
28 cpt deficiency, hepatic, type ia 11.0
29 glutaricaciduria, type i 11.0
30 fructose-1,6-bisphosphatase deficiency 11.0
31 sarcosinemia 11.0
32 acrodermatitis enteropathica 11.0
33 tay-sachs disease 11.0
34 homocarnosinosis 11.0
35 dihydropyrimidine dehydrogenase deficiency 11.0
36 mcardle disease 11.0
37 glycogen storage disease iiia 11.0
38 glycogen storage disease ii 11.0
39 glycogen storage disease vii 11.0
40 disorders of intracellular cobalamin metabolism 10.9
41 abdominal obesity-metabolic syndrome 10.9
42 pyruvate dehydrogenase e1-alpha deficiency 10.9
43 carnitine palmitoyltransferase ii deficiency 10.9
44 dihydrolipoamide dehydrogenase deficiency 10.9
45 n-acetylglutamate synthase deficiency 10.9
46 hmg-coa synthase-2 deficiency 10.9
47 carnitine-acylcarnitine translocase deficiency 10.9
48 hartnup disorder 10.9
49 molybdenum cofactor deficiency b 10.9
50 muscle glycogenosis 10.9

Comorbidity relations with Abdominal Obesity-Metabolic Syndrome 1 via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Encephalopathy Heart Disease

Graphical network of the top 20 diseases related to Abdominal Obesity-Metabolic Syndrome 1:



Diseases related to Abdominal Obesity-Metabolic Syndrome 1

Symptoms & Phenotypes for Abdominal Obesity-Metabolic Syndrome 1

Clinical features from OMIM:

605552

UMLS symptoms related to Abdominal Obesity-Metabolic Syndrome 1:


emaciation, angina pectoris, chest pain, edema

MGI Mouse Phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 INS LEP LPL MTTP PAH PPARA
2 growth/size/body region MP:0005378 10.36 SLC2A4 PAH PPARA PPARD PPARG SCD
3 cardiovascular system MP:0005385 10.31 ACADM ADIPOQ APOB ETFDH HSD11B1 INS
4 adipose tissue MP:0005375 10.29 ADIPOQ HSD11B1 INS LEP LPL PPARA
5 immune system MP:0005387 10.25 HGD HSD11B1 INS LEP PPARA PPARD
6 liver/biliary system MP:0005370 10.25 INS LEP LPL MTTP PPARA PPARD
7 cellular MP:0005384 10.22 ADIPOQ APOB FAH HSD11B1 INS LEP
8 integument MP:0010771 10.11 ADIPOQ HSD11B1 INS LEP LPL PAH
9 mortality/aging MP:0010768 10.1 ACADM ADIPOQ APOB ETFDH FAH INS
10 muscle MP:0005369 9.9 ACADM ADIPOQ APOB HSD11B1 INS LEP
11 neoplasm MP:0002006 9.43 LEP PPARD PPARG SERPINE1 ADIPOQ FAH
12 renal/urinary system MP:0005367 9.28 SCD SERPINE1 ADIPOQ FAH HGD INS

Drugs & Therapeutics for Abdominal Obesity-Metabolic Syndrome 1

Drugs for Abdominal Obesity-Metabolic Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 778)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ezetimibe Approved Phase 4,Phase 3 163222-33-1 150311
2
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
3
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
4
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 111025-46-8 4829
5
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
6
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 1 137862-53-4 60846
7
Eplerenone Approved Phase 4,Phase 3 107724-20-9 150310 443872
8
Spironolactone Approved Phase 4,Phase 3 1952-01-7, 52-01-7 5833
9
Cilostazol Approved Phase 4 73963-72-1 2754
10
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-23-7 5754 657311
11
Metyrapone Approved Phase 4 54-36-4 4174
12
Orlistat Approved, Investigational Phase 4,Phase 1,Phase 2 96829-58-2 3034010
13
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1 58-18-4 6010
14
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
15
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1 88150-42-9 2162
16
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 1,Early Phase 1 58-93-5 3639
17
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
18
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
19
Olmesartan Approved, Investigational Phase 4,Phase 3 144689-24-7, 144689-63-4 158781 130881
20
Cortisone acetate Approved Phase 4,Phase 2 1950-04-4, 50-04-4 5745
21
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2 51-43-4 5816
22
Zinc Approved Phase 4,Phase 2,Phase 1 7440-66-6 32051 23994
23
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
24
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2 57-63-6 5991
25 Moxonidine Approved Phase 4 75438-57-2 4810
26
Clozapine Approved Phase 4,Phase 2 5786-21-0 2818
27
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
28
Haloperidol Approved Phase 4 52-86-8 3559
29
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1 132539-06-1 4585
30
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
31
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
32
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
33
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 122320-73-4 77999
34
Fenofibrate Approved Phase 4,Phase 3,Phase 2 49562-28-9 3339
35
Allopurinol Approved Phase 4,Phase 2 315-30-0 2094
36
Cisplatin Approved Phase 4,Phase 2 15663-27-1 84093 441203 2767
37
Ethanol Approved Phase 4,Phase 3 64-17-5 702
38
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2 141758-74-9 15991534
39
Ticlopidine Approved Phase 4 55142-85-3 5472
40
Fluvastatin Approved Phase 4,Phase 3 93957-54-1 1548972
41
Pitavastatin Approved Phase 4,Phase 1 147511-69-1, 147526-32-7 6366718 5282452
42 Titanium dioxide Approved Phase 4,Phase 3,Phase 2 13463-67-7
43
Cilnidipine Approved Phase 4 132203-70-4 5282138
44
Nifedipine Approved Phase 4 21829-25-4 4485
45
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 2 144701-48-4 65999
46
Trandolapril Approved Phase 4 87679-37-6 5484727
47
Verapamil Approved Phase 4 52-53-9 2520
48
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
49
Enalaprilat Approved Phase 4 76420-72-9 6917719
50
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171

Interventional clinical trials:

(show top 50) (show all 1864)
id Name Status NCT ID Phase
1 Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome. Unknown status NCT00988364 Phase 4
2 Effect of Growth Hormone in Metabolic Syndrome Unknown status NCT00307411 Phase 4
3 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4
4 Trial of Supplementation With Aged Garlic Extract to Improve Endothelial Function in Patients With Metabolic Syndrome Unknown status NCT01168700 Phase 4
5 Metformin in Postmenopausal Women With Metabolic Syndrome Unknown status NCT01342744 Phase 4
6 Pioglitazone Vs Placebo in Combination With Niacin Extended Release on Low HDL Unknown status NCT00300365 Phase 4
7 The ACT-OUT Trial: ACTivity OUTcomes Based on High Carbohydrate or High Fat Diet in Metabolic Syndrome Unknown status NCT01357382 Phase 4
8 Ranolazine, Ethnicity and the Metabolic Syndrome Unknown status NCT01304095 Phase 4
9 Continuous Positive Airway Pressure in Sleep Apnea Syndrome: Effects on Metabolic Syndrome and Cardiac Damage Unknown status NCT00517777 Phase 4
10 Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study) Unknown status NCT00790946 Phase 4
11 Diurnal Variation of Plasminogen Activator Inhibitor-1 Unknown status NCT00515021 Phase 4
12 Rajavithi Health Promotion Project (Population Base Cohort) Unknown status NCT00368095 Phase 4
13 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness Unknown status NCT00573950 Phase 4
14 Cortisol and Nutritional Sympathetic Responsiveness Unknown status NCT01620684 Phase 4
15 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4
16 Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men Unknown status NCT00700024 Phase 4
17 Efficacy and Safety of Lobeglitazone Versus Sitagliptin Unknown status NCT02480465 Phase 4
18 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4
19 The Incidence and Treatment of Insulin Resistance Among Men With Erectile Dysfunction Unknown status NCT00284960 Phase 4
20 The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4
21 Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome Unknown status NCT01271374 Phase 4
22 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Unknown status NCT02277587 Phase 4
23 Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
24 Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Unknown status NCT00155350 Phase 4
25 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4
26 A Trial to Study the Effect of Long Term Vitamin D Supplementation on Insulin Sensitivity Unknown status NCT01052181 Phase 4
27 PCOS, Therapy and Markers of Cardiovascular Risk Unknown status NCT01798875 Phase 4
28 Korean AMADEUS Study Unknown status NCT01239849 Phase 4
29 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4
30 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4
31 Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes Unknown status NCT02236481 Phase 4
32 Curcumin for Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4
33 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4
34 Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia Unknown status NCT00395915 Phase 4
35 Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients Unknown status NCT00135460 Phase 4
36 PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome Completed NCT00296803 Phase 4
37 An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics Completed NCT00448630 Phase 4
38 ROMEO (Rosuvastatin in Metabolic syndrOme) Completed NCT00395486 Phase 4
39 Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion Completed NCT02113241 Phase 4
40 Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) Completed NCT00416741 Phase 4
41 Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome Completed NCT00138528 Phase 4
42 Cardiovascular Risk Evaluation in Clinical Practice in Metabolic Syndrome Patients Completed NCT00171548 Phase 4
43 The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome Completed NCT00664742 Phase 4
44 Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome Completed NCT00640276 Phase 4
45 Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome Completed NCT00815659 Phase 4
46 Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome Completed NCT00110422 Phase 4
47 Mesoglycan, Vascular Reactivity and Metabolic Syndrome Completed NCT02254850 Phase 4
48 The Effects of Cilnidipine on Metabolic Syndrome Improvement Completed NCT00325936 Phase 4
49 The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome Completed NCT00926341 Phase 4
50 Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome Completed NCT00335699 Phase 4

Search NIH Clinical Center for Abdominal Obesity-Metabolic Syndrome 1

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: metabolic syndrome x

Genetic Tests for Abdominal Obesity-Metabolic Syndrome 1

Genetic tests related to Abdominal Obesity-Metabolic Syndrome 1:

id Genetic test Affiliating Genes
1 Metabolic Syndrome X 29

Anatomical Context for Abdominal Obesity-Metabolic Syndrome 1

Publications for Abdominal Obesity-Metabolic Syndrome 1

Variations for Abdominal Obesity-Metabolic Syndrome 1

ClinVar genetic disease variations for Abdominal Obesity-Metabolic Syndrome 1:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 GHRL NM_001134944.1(GHRL): c.178C> A (p.Leu60Met) single nucleotide variant Pathogenic,risk factor rs696217 GRCh37 Chromosome 3, 10331457: 10331457

Copy number variations for Abdominal Obesity-Metabolic Syndrome 1 from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 267520 mtDNA 1 16569 Copy number Metabolic syndrome

Expression for Abdominal Obesity-Metabolic Syndrome 1

Search GEO for disease gene expression data for Abdominal Obesity-Metabolic Syndrome 1.

Pathways for Abdominal Obesity-Metabolic Syndrome 1

Pathways related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 ACADM ADIPOQ APOB ETFDH FAH HGD
2
Show member pathways
13.34 ADIPOQ ETFDH INS LEP LPL PPARA
3
Show member pathways
12.68 ACADM ADIPOQ LEP LPL PPARA PPARD
4
Show member pathways
12.65 ADIPOQ INS LEP RETN SLC2A4
5
Show member pathways
12.39 INS LPL SCD SLC2A4
6 12.39 ADIPOQ INS PPARG SCD SLC2A4
7
Show member pathways
12.33 ADIPOQ INS LEP PPARG SCD SLC2A4
9
Show member pathways
11.81 INS PPARA SLC2A4
10
Show member pathways
11.74 ADIPOQ INS SLC2A4
11
Show member pathways
11.71 PPARA PPARD PPARG
12 11.64 INS LPL PPARG SCD
13 11.62 ADIPOQ INS LEP LPL PPARG SLC2A4
14
Show member pathways
11.61 FAH HGD PAH
15 11.6 ADIPOQ LEP PPARA SLC2A4
16
Show member pathways
11.56 APOB LPL MTTP
17 11.48 ADIPOQ INS LEP LPL PPARA PPARD
18 11.36 ACADM ADIPOQ LPL PPARA PPARD PPARG
19 11.23 PPARA PPARD PPARG
20 11.07 ADIPOQ LEP PPARG
21 11.01 ADIPOQ LEP PPARG SLC2A4
22 10.8 INS SLC2A4

GO Terms for Abdominal Obesity-Metabolic Syndrome 1

Cellular components related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.32 ACADM ADIPOQ APOB FAH HGD LPL
2 endosome lumen GO:0031904 9.16 APOB INS
3 chylomicron GO:0042627 8.96 APOB LPL

Biological processes related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
id Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.99 ACADM PPARA PPARD PPARG
2 response to organic substance GO:0010033 9.89 APOB PPARD PPARG
3 wound healing GO:0042060 9.89 INS PPARA PPARD
4 regulation of lipid metabolic process GO:0019216 9.88 ACADM PPARA PPARG
5 cholesterol metabolic process GO:0008203 9.88 APOB LEP PPARD
6 cellular response to insulin stimulus GO:0032869 9.88 ADIPOQ PPARG SLC2A4
7 response to nutrient GO:0007584 9.87 ADIPOQ LEP PPARG
8 negative regulation of inflammatory response GO:0050728 9.87 ADIPOQ PPARA PPARD
9 response to glucose GO:0009749 9.85 ADIPOQ LPL PPARD
10 response to insulin GO:0032868 9.85 LEP PPARA RETN
11 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.84 INS LEP PPARD
12 cholesterol homeostasis GO:0042632 9.83 APOB LPL MTTP
13 steroid hormone mediated signaling pathway GO:0043401 9.81 PPARA PPARD PPARG
14 circadian rhythm GO:0007623 9.81 ADIPOQ LEP MTTP SERPINE1
15 glucose metabolic process GO:0006006 9.78 ADIPOQ INS LEP PPARD
16 response to activity GO:0014823 9.77 ADIPOQ LEP PPARD
17 intracellular receptor signaling pathway GO:0030522 9.76 PPARA PPARD PPARG
18 placenta development GO:0001890 9.75 LEP PPARD PPARG
19 response to cold GO:0009409 9.74 ACADM LPL PPARG
20 glucose transport GO:0015758 9.73 INS PPARD SLC2A4
21 positive regulation of cellular protein metabolic process GO:0032270 9.72 ADIPOQ INS
22 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.72 APOB LPL
23 fatty acid transport GO:0015908 9.72 PPARA PPARD
24 fatty acid catabolic process GO:0009062 9.71 LEP PPARD
25 negative regulation of gluconeogenesis GO:0045721 9.71 ADIPOQ INS
26 positive regulation of insulin receptor signaling pathway GO:0046628 9.71 INS LEP
27 negative regulation of smooth muscle cell proliferation GO:0048662 9.7 ADIPOQ PPARD PPARG
28 very-low-density lipoprotein particle assembly GO:0034379 9.69 APOB MTTP
29 lipoprotein biosynthetic process GO:0042158 9.69 APOB MTTP
30 regulation of gluconeogenesis GO:0006111 9.68 ACADM LEP
31 chylomicron assembly GO:0034378 9.68 APOB MTTP
32 negative regulation of pri-miRNA transcription from RNA polymerase II promoter GO:1902894 9.68 PPARA PPARD
33 chylomicron remodeling GO:0034371 9.67 APOB LPL
34 regulation of fat cell differentiation GO:0045598 9.67 LEP PPARD PPARG
35 fatty acid beta-oxidation using acyl-CoA dehydrogenase GO:0033539 9.65 ACADM ETFDH
36 negative regulation of acute inflammatory response GO:0002674 9.65 INS PPARG
37 aromatic amino acid family metabolic process GO:0009072 9.65 FAH PAH
38 negative regulation of appetite GO:0032099 9.64 LEP PPARA
39 negative regulation of collagen biosynthetic process GO:0032966 9.63 PPARD PPARG
40 positive regulation of cholesterol storage GO:0010886 9.63 APOB LPL
41 fatty acid oxidation GO:0019395 9.63 ADIPOQ PPARD PPARG
42 negative regulation of cholesterol storage GO:0010887 9.62 PPARA PPARG
43 tyrosine catabolic process GO:0006572 9.62 FAH HGD
44 lipoprotein metabolic process GO:0042157 9.62 APOB LPL MTTP PPARA
45 negative regulation of feeding behavior GO:2000252 9.61 INS RETN
46 positive regulation of fatty acid oxidation GO:0046321 9.61 PPARA PPARG
47 lipoprotein transport GO:0042953 9.61 APOB MTTP PPARG
48 negative regulation of sequestering of triglyceride GO:0010891 9.59 PPARA PPARG
49 negative regulation of smooth muscle cell migration GO:0014912 9.58 ADIPOQ PPARD SERPINE1
50 cellular response to prostaglandin stimulus GO:0071379 9.55 APOB PPARG

Molecular functions related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 lipid binding GO:0008289 9.67 APOB MTTP PPARA PPARD
2 oxidoreductase activity GO:0016491 9.63 ACADM ETFDH HGD HSD11B1 PAH SCD
3 drug binding GO:0008144 9.5 PPARA PPARD PPARG
4 steroid hormone receptor activity GO:0003707 9.43 PPARA PPARD PPARG
5 apolipoprotein binding GO:0034185 9.4 LPL MTTP
6 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 9.13 PPARA PPARD PPARG
7 hormone activity GO:0005179 8.92 ADIPOQ INS LEP RETN

Sources for Abdominal Obesity-Metabolic Syndrome 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....